US 12,291,749 B2
DNA methylation and genotype specific biomarker for predicting post-traumatic stress disorder
Zachary Kaminsky, Ottawa (CA); and Marco Paul Maria Boks, Utrecht (NL)
Assigned to The Johns Hopkins University, Baltimore, MD (US); and UMC Utrecht Holding B.V., Utrecht (NL)
Filed by THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US); and UMC Utrecht Holding B.V., Utrecht (NL)
Filed on Jun. 29, 2021, as Appl. No. 17/362,273.
Application 17/362,273 is a continuation of application No. 15/517,215, granted, now 11,072,828, previously published as PCT/US2015/054194, filed on Oct. 6, 2015.
Claims priority of provisional application 62/060,503, filed on Oct. 6, 2014.
Prior Publication US 2021/0404003 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C07H 21/04 (2006.01); C12Q 1/6883 (2018.01); G01N 33/92 (2006.01)
CPC C12Q 1/6883 (2013.01) [G01N 33/92 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/156 (2013.01); G01N 2800/28 (2013.01); G01N 2800/301 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7004 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method for treating post-traumatic stress disorder (PTSD) in a subject comprising the step of administering a PTSD treatment to a subject predicted to have PTSD using a method comprising the steps of:
(a) measuring DNA methylation level of a CpG dinucleotide located on the minus strand of chromosome 17, at position 57187729 from DNA isolated from a sample collected from the subject;
(b) detecting the genotype at the single nucleotide polymorphism (SNP) rs7208505, from DNA isolated from a sample collected from the subject; and
(c) using a linear model that incorporates the measured DNA methylation level and genotype at rs7208505, age and sex to predict PTSD in the subject,
wherein the PTSD treatment comprises psychotherapy, antidepressants and/or anti-anxiety medication.